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Abstract
Though they may offer valuable patient and disease information that is impossi-
ble to study in a randomized trial, clinical disease registries also require special care
and attention in causal inference. Registry data may be incomplete, inconsistent, and
subject to confounding. In this paper we aim to address several analytical issues in
estimating treatment effects that plague clinical registries such as the Emory amy-
otrophic lateral sclerosis (ALS) Clinic Registry. When attempting to assess the effect
of a surgical insertion of a percutaneous endoscopic gastrostomy (PEG) tube on body
mass index (BMI) using the data from the ALS Clinic Registry, one must combat
issues of confounding, censoring by death, and missing outcome data that have not
been addressed in previous studies of PEG. We propose a causal inference framework
for estimating the survivor average causal effect (SACE) of PEG, which incorporates
a model for generalized propensity scores to correct for confounding by pre-treatment
variables, a model for principal stratification to account for censoring by death, and
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a model for the missing data mechanism. Applying the proposed framework to the
ALS Clinic Registry Data, our analysis shows that PEG has a positive SACE on BMI
at month 18 post-baseline; our results likely offer more definitive answers regarding
the effect of PEG than previous studies of PEG.
Keywords: Censoring by death; Confounding; Generalized propensity scores; Missing data;
Observational study; Principal stratification.
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1 Introduction
While observational data from disease registries can be used to assess treatment effects, they
are often fraught with analytical challenges. This is particularly true of a disease with high
disability and mortality rates as issues of unmeasured data often occur due to a patient’s
absence or death. Our work is motivated by the analysis of data from an amyotrophic lateral
sclerosis (ALS) Clinic Registry, aimed at estimating the effect of a palliative treatment,
percutaneous endoscopic gastrostomy (PEG) on body mass index (BMI), a measure of
nutritional management and quality of life. ALS is a neurodegenerative disorder with a
very poor prognosis (Gelinas and Miller, 2000; Procaccini and Nemergut, 2008). Currently
there is no known cure for ALS and existing treatment procedures for ALS patients are
mostly palliative; there has been substantial interest in assessing effects of these palliative
procedures on quality of life (Miller et al., 2009).
Dysphagia, or difficulty in swallowing, affects almost all patients with ALS, and sub-
sequently along with muscle atrophy and hypermetabolism causes malnutrition amongst
the ALS patient population. Nutritional management is key in disease management and
palliative care (Desport et al., 2006; Muscaritoli et al., 2012). PEG, a surgically inserted
tube providing enteral nutrition, is generally considered when an ALS patient’s nutritional
status deteriorates and weight loss is greater than 10% of the baseline weight (Goyal and
Mozaffar, 2014; Park et al., 1992), though patients may elect not to receive PEG for other
reasons. While some studies have shown that PEG tube insertion offers some benefits in
stabilizing or even increasing body weight, the overall results regarding the effect of PEG
on weight or BMI are inconclusive, and in particular the long term benefits of the procedure
are uncertain (Kasarskis et al., 1996; Katzberg and Benatar, 2011; Mazzini et al., 1995).
One challenge for assessing the effect of PEG in ALS patients is that randomized studies
are not ethically feasible, since PEG placement has long been recommended as standard
of care in ALS clinics for patients with nutritional compromise (Miller et al., 2009). As a
result, the effect of PEG has been evaluated using observational data, and previous stud-
ies did not adequately address analytical issues including confounding and missing data
that were commonly encountered. In addition, the existing studies had small to moderate
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sample sizes, limiting the generalizability of their findings.
The Emory ALS Clinic Registry has several notable strengths, making it well-suited for
assessing the effect of PEG. It includes more than 1000 patients with long-term follow-up
and a wide range of relevant clinical variables such as BMI, vital capacity (VC), forced vital
capacity (FVC), negative inspiratory force (NIF), and ALS Functional Rating Scale Revised
score (ALSFRS-R). In particular, ALSFRS-R is a measure of disease progression and is
not always collected in large ALS registries. However, the data present several analytical
challenges to estimating a causal effect of PEG. First, insertion of PEG is not randomized,
which may lead to confounding by pre-treatment variables. Second, due to the fatal and
fast-progressing nature of ALS outcome measurements may be “censored by death,” i.e,
a patient dies before the outcome of interest can be measured (Zhang and Rubin, 2003;
Rubin, 2006). Third, for those who are not “censored by death,” the outcome may be
missing due to various reasons.
In the context of Rubin’s Causal Model, principal stratification, first described in detail
in Frangakis and Rubin (2002), offers a framework for causal inference in the presence of a
confounding post-treatment variable, such as censoring by death. Subsequently, Zhang and
Rubin (2003) extended this approach to cases where a post-treatment variable such as sur-
vival or graduation “censors” the outcome of interest. Zhang et al. (2009) further outlined
specific modeling approaches for the identification of survivor average causal effect (SACE)
within the principal stratification framework. These existing works in this area, however,
analyzed data from randomized studies, assuring complete collection of outcome data and,
more importantly, avoiding the issues of confounding, an advantage not guaranteed in our
retrospective clinic registry data.
More recently, Frumento et al. (2012) addressed post-treatment variables and missing
outcome data simultaneously within a principal stratification framework in a randomized
study. However, the Emory ALS Clinic Registry data introduce some unique challenges
that were not present in the analysis of Frumento et al. (2012) and require new analytical
approaches. In particular, our study treatment is not randomized and includes a component
of time to treatment, leading to potential confounding by pre-treatment variables. Further-
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more, both treatment and outcome measurement are subject to censoring by death in our
study. Finally, missing outcome data in our study are due to the observational nature of
the study, and have different implications compared to the missing outcomes in Frumento
et al. (2012). Therefore, while some of the same tools are utilized in our work, the proposed
framework addresses important new issues.
It is particularly important to address potential confounding by pre-treatment variables
in a principal stratification model, because Frangakis and Rubin (2002) defined principal
stratification in a randomized experiment. When such confounding may be present, either
as residual confounding in a randomized clinical trial or due to observational data, Schwartz
et al. (2012) showed that the resulting principal effect estimate is likely to be biased. Of
the many methods for handling confounding, a popular choice is the propensity score
introduced by Rosenbaum and Rubin (1983). The propensity score provides a means of
balancing pre-treatment variables across treatment groups, a result that would otherwise
be guaranteed if a randomized study design is used. Though propensity scores were initially
introduced for balancing treatment assignment groups when treatment is binary, other
authors have extended these methods to non-binary treatment assignment models, such as
generalized propensity score methods (Imai and Van Dyk, 2004; Hirano and Imbens, 2004).
These methods allow for balancing pre-treatment variables when treatment assignment is
categorical or continuous. A recent work by Jo and Stuart (2009) used propensity scores
within a principal stratification framework, not for the removal of confounding as the study
was randomized, but instead to predict principal strata membership in a matched analysis,
again different from our setting. Furthermore, propensity score methods for non-binary
treatment assignment have not yet been employed for conditional ignorability in a principal
stratification framework when outcomes may be missing.
To account for aforementioned complicating analytical issues, we develop a causal infer-
ence approach for estimating the survivor average causal effect (SACE) of PEG. Building on
the principal stratification framework to account for censoring by death (i.e., confounding
by a post-treatment variable), our approach uses generalized propensity scores to correct
for confounding by pre-treatment variables and it also accounts for missing outcome data
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by incorporating a model for the missing data mechanism. Although it is developed for the
specific application, our approach can be applied to analysis of other observational stud-
ies that are subject to similar issues. The remainder of the article is organized as follows.
First, we introduce the data and notation in Section 2. We present our framework for causal
inference in Section 3 and a Bayesian inference procedure in Section 4. In Section 5, we
apply the proposed approach to the Emory ALS data. We conclude this paper with some
discussion remarks in Section 6.
2 Data Structure in the ALS Registry
In the analysis of the ALS Clinic Registry, our goal is to assess the effect of PEG on BMI
(denoted by Y ) at to = 18 months post-baseline; without loss of generality we assume that
Y ∈ R. We denote by D the set of patient baseline characteristics and by TS the survival
time post-baseline confirmed by Social Security database records, noting that all patients
in our data set died. The surgical insertion of a PEG tube may be administered at any
time post-baseline given patient choice. Let Z be the binary indicator such that Z = 1 if a
patient received PEG prior to the time of outcome measurement to and Z = 0 if otherwise;
let TZ denote time to treatment. It follows that patients untreated prior to t
o have values
Z = 0 and TZ = TS if they did not survive until t
o, or Z = 0 and TZ = t
o if they survived
past to. For those who died prior to to, Y is undefined and is known as “censored by death.”
For those who are alive at to, Y is defined but may be missing due to other reasons and let
M be the binary indicator such that M = 1 if Y is missing and M = 0 if Y is observed. Of
note, for patients with S = 0 who were “censored by death,” both Y and M are undefined,
denoted by “*”, following the notation of Zhang and Rubin (2003). This extends the sample
space for Y to {R, ∗} and for M to {0, 1, ∗}.
3 Causal Inference Framework
As earlier defined, the binary indicator for treatment from baseline until to (time of outcome
measurement) is Z and the outcome of interest is Y . A post-treatment indicator of survival
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Baseline 
TZ < to 
Z = 1 
TS > to 
S(1) = 1 
Y(1) observed 
M = 0 
Y(1) missing 
M = 1 
TS < to 
S(1) = 0 
Y(1) & M undefined 
TZ > to 
Z = 0 
TS > to 
S(0) = 1 
Y(0) observed 
M = 0 
Y(0) missing 
M = 1 
TS < to 
S(0) = 0 
Y(0) & M undefined  
Figure 1: Potential outcomes for all patients given survival and treatment status.
past the to is S. Following the Rubin Causal Model (Holland, 1986), we define potential
outcomes Y = {(Yi(0), Yi(1)) for i = 1 . . . n} and S = {(Si(0), Si(1)) for i = 1...n} under
the two treatment options Z = 0 and 1. For simplicity, we suppress i in what follows if it
does not create ambiguity.
Figure 1 illustrates the potential outcomes in the Emory ALS data. For example, pa-
tients who are treated prior to time of outcome measurement (TZ > t
o) may follow one of
two paths: survival until to (S = 1) or death prior to to (S = 0). Those individuals who
survive may have observed Y , as designated by the darkest shaded box in Figure 1, or have
missing Y as designated in the medium shaded box. Patients who die before to have both
Y and M undefined, i.e., censored by death, as designated by the lightest shaded box.
In the presence of censoring by death, we use post treatment survival status to define
four potential principal strata (G) by (Si(0), Si(1)), namely, LL, LD, DL, and DD. Indi-
viduals who are in the LL stratum are those who would be alive at time to regardless of
treatment. Those individuals who are in the LD stratum would be alive if they received
the treatment but would not be alive if they did not and those who are in the DL stratum
would not be alive if they receive the treatment, but would be alive if they did not. Finally,
individuals in the DD are those who would die prior to time to regardless of treatment. A
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causal effect of treatment is only estimable in strata where individuals would be alive and
therefore have a measurable outcome, regardless of treatment status. As such, the causal
effect is estimable in the LL stratum only. Specifically, the Survivor Average Causal Effect
(SACE) is defined as the difference in Y between treated and untreated individuals in the
LL stratum.
However, we do not get to observe G since we only know the survival status given the
observed treatment status. Based on (Z, S), there are four observed groups denoted by
O(Z, S): O(1, 1), O(1, 0), O(0, 1), and O(0, 0). Each of these observed groups is a mixture
of the principal strata. Specifically, O(1,1) is a mixture of individuals from the LL and LD
strata, O(1,0) is comprised of individuals from the LL and DL strata, O(0,1) is comprised
of individuals from the DD and DL strata, and O(0,0) is comprised of individuals from the
DD and LD strata. In addition, based on (Z, S,M), we have six observed groups denoted
by O(Z, S,M), namely, O(1,1,1), O(1,1,0), O(1,0,-), O(0,1,1), O(0,1,0), O(0,0,-); see Table
1. The two original observed groups with S = 1, namely, O(1,1) and O(0,1), are each
divided into two subgroups based on whether Y is observed or missing. The groups with
S = 0 do not need to be divided further, since M is undefined.
3.1 Assumptions
In our causal inference framework, we adopt two standard assumptions, the Stable Unit
Treatment Value Assumption (SUTVA) as defined by Cox in 1958 and further elaborated
in Rubin (1980) and the Strong Ignorability of Treatment Assignment (Rosenbaum and
Rubin, 1983).
Assumption 1 [SUTVA] The potential outcomes of any unit is independent of the treat-
ment status of the other units given D.
Assumption 2 [Strong Ignorability of Treatment Assignment] (Yi(0), Yi(1)) and (Si(0), Si(1))
(or equivalently G) are independent of Z given D.
Regarding the missing data mechanism for Y , we consider two assumptions, a latent
ignorability (Frangakis and Rubin, 1999) and a standard ignorability (Little and Rubin,
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2002).
Assumption 3 [Latent Ignorable Missingness]M does not depend on the missing values or
parameters of the data distribution conditional on D and G; particularly, M is independent
of Y given D and G.
Assumption 4 [Ignorable Missingness] M does not depend on the missing values or pa-
rameters of the data distribution conditional on D; particularly, M is independent of Y
given D.
Since G is not completely known, the latent ignorable missingness in Assumption 3 is not
ignorable and it is necessary to model M in the modeling framework.
3.2 Data Likelihood
We define the complete data as (Yi, Si,Mi, Gi, Zi,Di) for i = 1, . . . , n, which under As-
sumption 1 constitute independent and identically distributed observations. Accordingly,
the observed data are represented as (Yi, Si,Mi, Gobs,i, Zi,Di), where Gobs,i is the set of
feasible principal strata that an individual may belong to given Zi and Si.
We first relate the distribution of the complete data (Yi, Si,Mi, Gi, Zi,Di) to the distri-
bution of the potential outcomes under Assumptions 1-3. We have
f(Yi|Si,Mi, Gi, Zi,Di) = f(Yi|Mi, Gi, Zi,Di) = f(Yi|Gi, Zi,Di) = f(Yi(Zi)|Gi,Di)
where the first equality is due to the fact that Si is redundant given Zi and Gi, the second
equality is due to Assumption 3, and the third equality is due to Assumption 2. In addition,
f(Si|Mi, Gi, Zi,Di) = 1, since Si is fully determined by Zi and Gi. From Assumption 2,
we have f(Gi|Zi,Di) = f(Gi|Di). Using these facts and Assumption 1, the complete data
likelihood can be written as∏
i
f(Yi, Si,Mi, Gi, Zi|Di)
=
∏
i
f(Yi|Si,Mi, Gi, Zi,Di)f(Si|Mi, Gi, Zi,Di)f(Mi|Gi, Zi,Di)f(Gi|Zi,Di)f(Zi|Di)
=
∏
i
f(Yi(Zi)|Gi,Di)f(Mi|Gi, Zi,Di)f(Gi|Di)f(Zi|Di), (1)
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where f(Yi(Zi)|Gi,Di) models the potential outcomes, f(Mi|Gi,Di) models the missing
data mechanism, f(Gi|Di) models the principal strata, and f(Zi|Di) models the treatment
assignment. Without loss of clarity, we define f(Yi|Gi,Di) = 1 if Yi is missing; in other
words, only observed Yi contributes to the first part of the complete data likelihood (1).
Assuming the parameters in f(Zi|Di) are distinct from the other parameters and f(Zi =
z|Di) > 0 for z = 0, 1, we can drop f(Zi|Di) from the complete data likelihood.
The observed data likelihood is considerably more complicated, since it involves mixture
distributions since we only observe Gobs,i and do not observe Gi. As shown in Section 4.4, a
data augmentation algorithm allows us to work with the complete data likelihood directly
and hence avoid the complicated observed data likelihood.
Since the treatment of interest includes a time-to-intervention component TZ , we use
generalized propensity scores in the spirit of Imai and Van Dyk (2004), Lu (2005) and
Hirano and Imbens (2004) to further accommodate this unique feature. Specifically, we
model TZ which may be censored by TS using a Cox proportional hazards (PH) model
h(t) = h0(t) exp
(
βTD
)
and use its linear predictor βTD as the generalized propensity
score, denoted by PS. Along the lines of Imai and Van Dyk (2004) and Lu (2005), it
follows from Assumptions 1 and 2 that Z is independent of (Yi(0), Yi(1)) and of (Si(0), Si(1))
conditional on PSi. Then the complete data likelihood (1) can be rewritten as∏
i
f(Yi(Zi)|Gi, PSi)f(Mi|Gi, Zi,Di)f(Gi|PSi), (2)
where f(Zi|Di) is dropped.
Alternatively, under Assumptions 1, 2 and 4, i.e., replacing the latent ignorable miss-
ingness with the ignorable missingness, the complete data likelihood (2) can be simplified
to ∏
i
f(Yi(Zi)|Gi, PSi)f(Mi|Zi,Di)f(Gi|PSi).
Assuming that its parameters are distinct from parameters in other models, f(Mi|Zi,Di)
can be dropped from the complete data likelihood, leading to∏
i
f(Yi(Zi)|Gi, PSi)f(Gi|PSi). (3)
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In Section 5, we analyze the ALS data using both (2) and (3) under the latent ignorable
missingness and the ignorable missingness, respectively.
4 Modeling Framework
In this section, we specify the model for each component of the complete data likelihood (2)
and then describe a Bayesian inference approach under Assumptions 1-3. The corresponding
inference approach under Assumptions 1-2 and 4 is simpler and can be derived along similar
lines.
4.1 Model for Potential Outcomes
For f(Yi(Zi)|Gi, PS) in (2), we assume that (Y (1), Y (2)) within each principal stratum
G = g have a normal distribution, fg, with parameters ηg and covariates X1,g that may
differ by strata. Also, individual likelihoods for Y are dependent on potential strata g, and
are represented by fg,i. Specifically, Y ∼ N(X1,gηg, σ2g) for g ∈ LL,LD,DL, where X1,LL
includes the column for intercept, Z, TZ , and PS. X1,LD and X1,DL include intercept and
PS but not Z and TZ as patients with an observed outcome in each of these strata are
either all treated or all untreated respectively. The regression coefficient for Z in the LL
stratum represents SACE and is of primary interest. Inclusion of TZ allows us to assess the
relationship between Y and time to treatment within those who receive the treatment.
4.2 Model for Principal Stratification
The probabilities of the four principal strata, denoted by (piLL, piLD, piDL, piDD), are modeled
using a multinomial logit model with a set of covariates denoted by X2 including PS. he
probability of a patient being in principal stratum g is given in equation (4), and individual
probabilities of principal strata are represented by pig,i. As in any multinomial logit model,
one category must be selected as a reference group.
pig = P (G = g|X2) = exp(X
T
2αg)∑
g′ exp (X
T
2αg′)
(4)
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Of the assumptions available for sharpening the bounds of effect estimates in the principal
stratification framework, a monotonicity assumption is often used, i.e., one of the principal
strata, say the DL group does not exist Zhang and Rubin (2003). While this monotonicity
assumption may be plausible if treatment is always beneficial on patient survival, it is also
possible that a subpopulation of weak patients would be not be able to withstand treatment
or recovery and may die shortly after treatment, but could stay alive if left untreated, when
evaluating an intrusive treatment. For such a data analysis, it may be appropriate to allow
all four principal strata to exist and to relax the assumption of monotonicity. In the ALS
data, the SACE for PEG is estimated both with and without the monotonicity assumption
to assess its impact.
4.3 Model for Missing Data Mechanism
As discussed before, M for patients with S = 0 is undefined, so it is only valid to model M
for those individuals in the LL stratum with treatment, the LL stratum without treatment,
the LD stratum with treatment, and the DL stratum without treatment. The model for
M is presented in (5).
φgz = Pr(M = 1|G = g, Z = z, S = 1) = e
X3θg,z
1 + eX3θg,z
(5)
where X3 is a set of covariates associated with the missing data mechanism. The individual
probability of missingness is dependent on strata and treatment value and is represented
by φgz,i. When Assumption 4 is used instead of Assumption 3, this model is not needed.
4.4 Bayesian Inference
Given the models specified in Section 4.1-4.3, the individual likelihoods for all possible
combinations of Z, S, and M are given in Table 1, where each cell value is the likelihood of
the complete data if G is known. The conditional probability of Gi = g given the observed
data is the ratio of each cell to the total of that row. Rows O(1, 0,−) and O(0, 0,−) are
included in Table 1 for a comprehensive understanding of the possible combinations of
treatment and survival, but individuals who fall into these groups do not have outcome
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Table 1: Individual likelihood by observed groups if Gi is known
Gi
Observed
Group O(Z, S,M) LL LD DL DD
O(1, 1, 0)
(1− φLL,1,i)× (1− φLD,1,i)×
- -
piLL,ifLL,i piLD,ifLD,i
O(1, 1, 1) φLL,1,ipiLL,i φLD,1,ipiLD,i - -
O(1, 0,−) - - piDL,i piDD,i
O(0, 1, 0)
(1− φLL,0,i)×
-
(1− φDL,0,i)×
-
piLL,ifLL,i piDL,ifDL,i
O(0, 1, 1) φLL,0,ipiLL,i - φDL,0,ipiDL,i -
O(0, 0,−) - piLD,i - piDD,i
data and hence do not contribute to the observed data likelihood. As such, these individuals
will only contribute to the model for the probability of principal strata, which is reflected
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in the observed data likelihood in equation (6).∏
i∈O(1,1,0)
{
(1− φLL,1,i)piLL,iN(X1,LL,iηLL, σ2LL) + (1− φLD,1,i)piLD,iN(X1,LD,iηLD, σ2LD)
}×
∏
i∈O(0,1,0)
{
(1− φLL,0,i)piLL,iN(X1,LL,iηLL, σ2LL) + (1− φDL,0,i)piDL,iN(X1,DL,iηDL, σ2DL)
}×
∏
i∈O(1,1,1)
{(φLL,1,i)piLL,i + (φLD,1,i)piLD,i}×
∏
i∈O(0,1,1)
{(φLL,0,i)piLL,i + (φDL,0,i)piDL,i}×
∏
i∈O(1,0,−)
{piDD,i + piDL,i}
∏
i∈O(0,0,−)
{piDD,i + piLD,i}
(6)
Prior distributions for the specified parameters in the observed data likelihood should
be chosen carefully, with thought to distributions that may be informative, proper, and
conjugate where appropriate. For this analysis, a conjugate multivariate normal prior dis-
tribution is assumed for ηg, ηg ∼ Normalp
(
µg, σ
2
gVg
)
. Similarly, a conjugate prior distri-
bution is assumed for σ2g , σ
2
g ∼ InverseGamma (νg, ωg). We choose diffused priors for αg
and θg,z.
Though the principal stratum of each individual is unknown, the observed treatment and
survival groups may be used to inform imputation of the principal stratum assignments.
Applying this idea, we use the Data Augmentation (DA) algorithm (Tanner and Wong,
1987) for posterior computation, in which information about the latent groups, namely, G,
is imputed and subsequently the posterior parameters distributions are simulated.
The DA algorithm includes two iterative and alternating steps to allow for posterior
inference. The first step, the Imputation or I-step, imputes the value of the principal stratum
G for each individual. This is accomplished by using the parameter values α
(k)
g , η
(k)
g , σ
2(k)
g ,
and θ(k)g,z (for approach 2 only) from the current approximation of posterior (from the kth
iteration) to generate G(k+1) by using the conditional probabilities that are given by taking
the ratio of each cell value to the row total in Table 1. These conditional probabilities,
ρO, are used in a Bernoulli distribution that imputes individual memberships to one of the
two principal strata that correspond with the observed group O. More specifically, at the
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(k+1) iteration, each individual has a probability of being in a stratum that depends on
their observed values (Z, S, M , Y , PS).
The P-step, or Posterior step, is then employed by using the imputed complete data set,
and the parameters {θ(k),
(
pi
(k)
g ,η
(k)
g , σ
2(k)
g
)
} can be updated to {θ(k+1),
(
pi
(k+1)
g ,η
(k+1)
g , σ
2(k+1)
g
)
}
by sampling from the full conditional distributions of each parameter based on the complete
data likelihood. Either a Gibbs Sampler or a Metropolis-Hastings (MH) Algorithm can be
employed for sampling. The details of the DA algorithm are provided in Web Appendices
A and B.
If we use Assumption 4 instead of Assumption 3, we can drop all terms involving φg,z
from Table 1 and use the complete data likelihood (3), leading to a simpler version of the
aforementioned DA algorithm.
5 Analysis of ALS Clinic Data
We apply the proposed approach to analysis of the data from patients who visited the
Emory ALS clinic at least once between 1997 and 2014. Patients are excluded from the
analysis for not having any follow up clinic visits from baseline to outcome measurement
at month 18 post-baseline or for having long survival times (>5 years post-baseline), re-
sulting in a cohort of N = 815 for our analyses. It has been noted that ALS patients with
long survival times are likely different from the other ALS patients (Mateen et al., 2010),
which may not be fully explained by clinical variables collected. Characteristics measured
at baseline for each individual include sex, race, age, site of disease onset, months from
symptom onset to baseline, months from diagnosis to baseline, body mass index (BMI),
vital capacity (VC), forced vital capacity (FVC), negative inspiratory force (NIF), and
ALS Functional Rating Scale Revised score (ALSFRS-R). Continuous variables, namely
age, months from symptom onset to baseline, months from diagnosis to baseline BMI, VC,
FVC, NIF, and ALSFRS-R, are standardized before being included as covariates for the
propensity score model and the modesls for principal stratification model, missing data
mechanism and outcomes. Since our focus is to handle missing outcome values, we impute
missing values in covariates prior to subsequent analysis using the proposed approach.
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Of the 275 treated patients, 32% or 89 individuals are alive 18 months from baseline,
while of the 540 untreated individuals, 34% or 186 individuals are alive at this time-point
(p = 0.606). Baseline measurements of BMI, FVC, and VC, as well as age at diagnosis,
survival until to, and proportion of white versus other races are not significantly different
between treated and untreated groups. However, clinically relevant differences between
treatment groups do exist. NIF and ALSFRS-R scores at baseline are significantly higher
for treated versus untreated individuals at a level of α = 0.05. Also the proportions of
female individuals and of individuals with spinal disease are significantly differnt for treated
individuals than untreated individuals (p = 0.040 and p< 0.001). Most interestingly, the
na¨ıve analysis that compares the outcome of interest, BMI at 18 months post-baseline,
across treatment groups indicates that treated individuals have a BMI that is 1 unit lower
than the untreated group, and this difference in significant (p = 0.021). These results
suggest that the effect of PEG may be confounded by variables that are different between
treated and untreated groups, hence it is important to use the generalized propensity score.
A table of patient characteristics by treatment status is available in the online Appendix
(Web Table 1).
The 275 survivors at to are significantly different from 540 non-surviving individuals
by nearly every clinical comparison, with only demographic characteristics of sex and race
being similar amongst the two groups, suggesting the need to adjust for the post-treatment
variable, censoring by death. Additionally there are significant differences amongst patients
with observed outcome and those with missing outcome data in, for example, BMI, FVC,
VC, NIF, and ALS FRS-R score at baseline. indicating that the missing completely at ran-
dom (MCAR) assumption is unrealistic and necessitates the use of the proposed approach
for handling missing data. Web Tables 2 and 3 providing support for these statements are
available in the online Appendix.
The SACE of PEG treatment is estimated using three modeling approaches. In addition
to the two approaches using Assumptions 3 (latent ignorable missingness) and 4 (ignorable
missingness) as described in Section 4.3, we consider a third approach that includes only
individuals with an outcome measurement at to, analogous to a complete-case analysis that
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essentially assumes that the outcomes are MCAR. We also apply the same set of methods
without the propensity score adjustment as well as with a monotonicity assumption, i.e.,
removal of the DL stratum (Zhang and Rubin, 2003). Finally, to allow for flexibility, poly-
nomial splines are used for incorporating the generalized propensity score in the models
with d denoting the degree of the polynomial spline. For all analyses, the MCMC algorithm
is run for a total of 5,000 iterations, with a burn-in period of 3000 iterations.
To identify the model that best fits the data, we use the deviance information criterion
(DIC) (Spiegelhalter et al., 2002). Models with smaller values of DIC are preferred to models
with larger values, and the best fit is indicated by a minimum DIC. Table 2 presents DIC for
each of the modeling approaches under different assumptions for missing data mechanism
with various degrees of polynomial splines for the propensity score. The models for all
three approaches with d = 4 have the lowest DIC, and therefore offer the best fit for each
modelling approach. Particularly, the model assuming latent ignorable missingness with
d = 4 has the lowest DIC among all models.
Table 2: Deviance Information Criterion (DIC) for analysis under Assumption 3 (latent ignorable
missingness), Assumption 4 (ignorable missingness) and MCAR, as d, the degree of polynomial
splines for propensity scores, varies.
d
0 1 2 3 4 5
Assumption 3 1702.55 1683.98 1668.20 1777.01 1658.00 2034.26
Assumption 4 1769.40 1722.59 1727.66 1733.74 1714.54 1719.51
MCAR 2715.46 2658.06 2655.16 2654.74 2653.52 3200.87
The top two rows of Table 3 present a comparison of the different modeling approaches
when propensity scores are included. Specifically, the results from the models with d = 4
are presented for each modelling approach, as these have been chosen best fitting models
according to DIC. In contrast to the na¨ıve analysis in Web Table 1 that shows a negative
effect of PEG, analyses under both Assumption 3 and Assumption 4 show that there is
a significant, positive SACE of PEG surgery on the outcome of BMI at 18 months post-
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Table 3: Estimates of SACE of PEG treatment (with 95% credible intervals) on BMI at 18 months
post-baseline Assumption 3 (latent ignorable missingness), Assumption 4 (ignorable missingness)
and MCAR with and without adjustment for propensity scores (PS) (N=815).
Effect Estimates
Latent Ignorable Ignorable
Missingness Missingness MCAR
With PS
Time to PEG
0.17 0.16 0.14
(-0.06,0.39) (-0.05,0.38) (-0.01,0.29)
Binary Indicator
3.09 3.17 2.28
(0.01,5.83) (0.14,6.24) (0.79,3.77)
Without PS
Time to PEG
0.24 0.24 0.20
(0.03,0.46) (0.03,0.45) (0.03,0.35)
Binary Indicator
0.45 0.56 -0.05
(-2.42,3.45) (-2.19,3.31) (-1.37,1.23)
baseline. Holding all else constant and assuming PEG insertion at or immediately after
baseline, BMI at 18 months increases by about 3 units for those individuals who receive
treatment when compared to those who are not treated among survivors. The effect of
time to treatment is also positive but not statistically significant. Noting that a higher
time to PEG (TZ) leads to a shorter time from PEG to the time of outcome measurement,
these results seem to suggest that the positive effect of PEG on BMI decreases gradually
after the treatment, i.e., the possibility for a waning long-term effect. Additionally, the
approach assuming MCAR indicates that the estimated effects of time to treatment and
binary treatment are smaller in magnitude than those estimated from the two approaches
under Assumptions 3 and 4, respectively.
The lower half of Table 3 presents the results from the three approaches without adjust-
ment for propensity scores in the estimation of the SACE of PEG treatment, showing some
changes in the magnitude of the effect estimates. On the one hand, removing the propen-
sity score from the models in Approaches 1 and 2, the time to treatment effect remains
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positive and is now significant. On the other hand, in these same models, the coefficient es-
timate for the binary treatment indicator is drastically smaller in magnitude and no longer
statistically significant. In the model that assumes MCAR and does not use propensity
scores, the coefficient estimate for the binary treatment indicator changes direction and is
non-significant.
In addition, the results, not provided, are not sensitive to the assumption of monotonic-
ity. This may be due to the small proportion of individuals in DL strata when all four
strata are considered. When monotonicity is not assumed, most patients are in the LL
and DD strata, with a LD and DL strata comprising less than 20% of the individuals in
total. It is conceivable then that reallocating such a small proportion of individuals when
removing the DL stratum would not substantially change the effect estimates of the other
strata.
Overall, the results in our analysis demonstrate a positive SACE of PEG, in contrast to
inconclusive results in magnitude, direction, and significance from previous observational
studies of PEG in association with weight or BMI. Given that our methodology is devel-
oped to account for the many complicating issues of an observational study that were not
addressed in previous studies, it is likely that the positive effect of PEG estimated in this
analysis is more definitive. As data collection is still ongoing in the ALS Clinic Registry,
the proposed approach can be applied to this registry in the future, potentially further
validating our current findings.
6 Discussion
Our current work represents the very first attempt to leverage the rich data in the Emory
ALS Clinic Registry for assessing the effect of PEG in a large ALS population. Our proposed
framework for causal inference addresses several challenges in the analysis of this data
that have not been accounted for in previous studies of PEG. Our results show a positive
effect of PEG placement on survivors that may be waning over time after insertion. Our
approach can be directly applied or extended to evaluate effects of PEG or other palliative
procedures such as the non-invasive positive pressure ventilation (NIPPV) (Miller et al.,
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2009) on additional outcomes that are of interest to clinicians including quality of life and
disease progression.
One limitation of our analysis is that we do not have data on the usage of PEG tube af-
ter its insertion. Of note, patients with PEG may elect not to use PEG for nutrition delivery
from time to time, thus the level of usage, similar to treatment adherence, could have an
impact on patient outcomes such as BMI. Additionally, while the use of propensity scores
within the principal stratification framework allows for the estimation of an unbiased prin-
cipal effect using observational data, the reliability of removing bias via propensity score
adjustment is predicated on the assumption of strongly ignorable treatment assignment,
which means there must be no unmeasured confounders. Partly based on our experience
from this work, a future prospective observational study, currently in the design and plan-
ning stage, will collect usage data for palliative procedures such as PEG and NIPPV as well
as additional potential confounders that are not collected or validated in standard clinical
settings. In addition, future applications of the proposed methods to other data with richer
measurements of confounders should further demonstrate the reduction of confounding.
Making adjustments for missing outcome data in the context of causal inference typ-
ically requires strong assumptions about the ignorability of the missing data mechanism
and creativity in the modeling framework. In our data application, the similar results under
Assumptions 3 and 4 indicate that the findings are not sensitive to the latent ignorable as-
sumption for this data, though we cannot empirically test this assumption. When in doubt,
further stratification by missingness of outcome data and within the principal stratification
framework may allow for additional flexibility in the assumptions imposed on the missing
data mechanism.
Future consideration may also be given to jointly modeling the propensity score with
the outcome model, missing data model, and principal strata model in a Bayesian frame-
work, similar in spirit with Zigler et al. (2013) and Zigler and Dominici (2014). This would
allow the quantities observed by in each of these three models to affect the posterior of
propensity score in each MCMC iteration. While this could provide a more robust propen-
sity score adjustment, Zigler et al. (2013) showed that the feedback between model stages
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in joint modeling can cause biased causal effect estimates if individual covariates are not
also adjusted for in the outcome model. This bias should be accounted for if one uses joint
modeling of the four models of outcome, missing data mechanism, propensity scores, and
principal strata.
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